PPARα and PPARγ activators suppress the monocyte-macrophage apoB-48 receptor

Journal of Lipid Research

Volumn 44, Issue 6, 2003, Pages 1224-1231

  Haraguchi, Go ^a   Kobayashi, Yasushi ^a   Brown, Matthew L ^b   Tanaka, Akira ^c   Isobe, Mitsuaki ^a   Gianturco, Sandra H ^b   Bradley, William A ^b  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b University of Alabama at Birmingham   (United States)

^c KANTO GAKUIN UNIVERSITY   (Japan)

Author keywords

Apolipoprotein B; Atherosclerosis; Foam cells; Lipoproteins; Peroxisome proliferator activated receptor; Triglyceride

Indexed keywords

ABC TRANSPORTER; APOLIPOPROTEIN B48 RECEPTOR; CELL RECEPTOR; CHYLOMICRON; LIGAND; LIPOPROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; DRUG EFFECT; DRUG RECEPTOR BINDING; FOAM CELL; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LIPID METABOLISM; MACROPHAGE; METABOLIC REGULATION; MONOCYTE; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; WESTERN BLOTTING;

EID: 0142105864     PISSN: 00222275     EISSN: None     Source Type: Journal    
DOI: 10.1194/jlr.M300077-JLR200     Document Type: Article

References (43)

1. Hokanson, J. E., and M. A. Austin. 1996. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk. 3: 213-219.
2. Brown, M. S., and J. L. Goldstein. 1983. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu. Rev. Biochem. 52: 223-261.
3. Gianturco, S. H., W. A. Bradley, A. M. Gotto, J. D. Morrisett, and D. L. Peavy. 1982. Hypertriglyceridemic very low density lipoproteins induce triglyceride synthesis and accumulation in mouse peritoneal macrophages. J. Clin. Invest. 70: 168-178.
4. Brown, M. L., M. P. Ramprasad, P. K. Umeda, A. Tanaka, Y. Kobayashi, T. Watanabe, H. Shimoyamada, W. L. Kuo, R. Li, R. Song, W. A. Bradley, and S. H. Gianturco. 2000. A macrophage receptor for apolipoprotein B48: cloning, expression, and atherosclerosis. Proc. Natl. Acad. Sci. USA. 97: 7488-7493.
5. Fredrickson, D. S., J. L. Goldstein, and M. S. Brown. 1978. The familial hyperlipoproteinemias. In The Metabolic Basis of Inherited Diseases. J. G. Stanbury, M. F. Wyngaarden, and D. S. Fredrickson, editors. McGraw-Hill, New York. 604-655.
6. Gianturco, S. H., S. G. Eskin, L. T. Navarro, C. J. Lahart, L. C. Smith, and A. M. Gotto. 1980. Abnormal effects of hypertriacylglycerolemic very low-density lipoproteins on 3-hydroxy-3-methylglutaryl-CoA reductase activity and viability of cultured bovine aortic endothelial cells. Biochim. Biophys. Acta. 618: 143-152.
7. Fielding, C. J., I. Vlodavsky, P. E. Fielding, and D. Gospodarowicz. 1979. Characteristics of chylomicron binding and lipid uptake by endothelial cells in culture. J. Biol. Chem. 254: 8861-8868.
8. Li, X-N., J. C. Kroon, R. L. Benza, J. M. Parks, V. K. Varma, W. A. Bradley, S. H. Gianturco, K. B. Taylor, J. R. Grammer, E. M. Tabengwa, and F. M. Booyse. 1996. Hypertriglyceridemic VLDL decreases plasminogen binding to endothelial cells and surface-localized fibrinolysis. Biochemistry. 35(19): 6080-6088.
9. Gianturco, S. H., A. M. Gotto, S. L. Hwang, J. B. Karlin, A. H. Lin, S. C. Prasad, and W. A. Bradley. 1983. Apolipoprotein E mediates uptake of Sf 100-400 hypertriglyceridemic very low density lipoproteins by the low density lipoprotein receptor pathway in normal human fibroblasts. J. Biol. Chem. 258: 4526-4533.
10. Bradley, W. A., S. L. Hwang, J. B. Karlin, A. H. Lin, S. C. Prasad, A. M. Gotto, and S. H. Gianturco. 1984. Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins. J. Biol. Chem. 259: 14728-14735.
11. Beisiegel, U., W. Weber, G. Ihrke, J. Herz, and K. K. Stanley. 1989. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 341: 162-164.
12. Kowal, R. C., J. Herz, J. L. Goldstein, V. Esser, and M. S. Brown. 1989. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. USA. 86: 5810-5814.
13. Yang, C. Y., S. H. Chen, S. H. Gianturco, W. A. Bradley, J. T. Sparrow, M. Tanimura, W. H. Li, D. A. Sparrow, H. DeLoof, M. Rosseneu, F. S. Lee, Z. W. Gu, A. M. Gotto, and L. Chan. 1986. Sequence, structure, receptor-binding domains and internal repeats of human apolipoprotein B-100. Nature. 323: 738-742.
14. Havel, R. J. 1985. George Lyman Duff memorial lecture. Role of the liver in atherosclerosis. Arteriosclerosis. 5: 569-580.
15. Brown, M. S., and J. L. Goldstein. 1986. A receptor-mediated pathway for cholesterol homeostasis. Science. 232: 34-47.
16. Nagata, Y., and D. B. Zilversmit. 1987. Blockade of intestinal lipoprotein clearance in rabbits injected with Triton WR 1339-ethyl oleate. J. Lipid Res. 28: 684-692.
17. Hussain, M. M., R. W. Mahley, J. K. Boyles, M. Fainaru, W. J. Brecht, and P. A. Lindquist. 1989. Chylomicron-chylomicron remnant clearance by liver and bone marrow in rabbits: factors that modify tissue-specific uptake. J. Biol. Chem. 264: 9571-9582.
18. Hussain, M. M., R. W. Mahley, J. K. Boyles, P. A. Lindquist, J. W. Brecht, and T. L. Innerarity. 1989. Chylomicron metabolism. Chylomicron uptake by bone marrow in different animal species. J. Biol. Chem. 264: 17931-17938.
19. Gianturco, S. H., A. H. Lin, S. L. Hwang, J. Young, S. A. Brown, D. P. Via, and W. A. Bradley. 1988. Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins. J. Clin. Invest. 82: 1633-1643.
20. Gianturco, S. H., M. P. Ramprasad, A. H. Lin, R. Song, and W. A. Bradley. 1994. Cellular binding site and membrane binding proteins for triglyceride-rich lipoproteins in human monocyte-macrophages and THP-1 monocytic cells. J. Lipid Res. 35: 1674-1687.
21. Gianturco, S. H., M. P. Ramprasad, R. Song, R. Li, M. L. Brown, and W. A. Bradley. 1998. Apolipoprotein B-48 or its apolipoprotein B-100 equivalent mediates the binding of triglyceride-rich lipoproteins to their unique human monocyte-macrophage receptor. Arterioscler. Thromb. Vasc. Biol. 18: 968-976.
22. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71: 343-353.
23. Zhang, S. H., R. L. Reddick, J. A. Piedrahita, and N. Maeda. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258: 468-471.
24. Brown, M. L., K. Yui, J. D. Smith, R. C. LeBoeuf, W. Weng, P. K. Umeda, R. Li, R. Song, S. H. Gianturco, and W. A. Bradley. 2002. The murine macrophage apoB-48 receptor gene (Apob-48r): homology to the human receptor. J. Lipid Res. 43: 1181-1191.
25. Barbier, O., I. P. Torra, Y. Duguay, C. Blanquart, J. C. Fruchart, C. Glineur, and B. Staels. 2002. Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 22: 717-726.
26. Wahli, W., O. Braissant, and B. Desvergne. 1995. Peroxisome proliferator activated receptors: transcriptional regulators of adipogenesis, lipid metabolism and more. Chem. Biol. 2: 261-266.
27. Ricote, M., A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass. 1998. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature. 391: 79-82.
28. Li, A. C., K. K. Brown, M. J. Silvestre, T. M. Willson, W. Palinski, and C. K. Glass. 2000. Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J. Clin. Invest. 106: 523-531.
29. Tontonoz, P., L. Nagy, J. G. Alvarez, V. A. Thomazy, and R. M. Evans. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93: 241-252.
30. Chinetti, G., S. Lestavel, V. Bocher, A. T. Remaley, B. Neve, I. P. Torra, E. Teissier, A. Minnich, M. Jaye, N. Duverger, H. B. Brewer, J. C. Fruchart, V. Clavey, and B. Staels. 2001. PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat. Med. 7: 53-58.
31. Marx, N., G. Sukhova, C. Murphy, P. Libby, and J. Plutzky. 1998. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am. J. Pathol. 153: 17-23.
32. Chinetti, G., F. G. Gbaguidi, S. Griglio, Z. Mallat, M. Antonucci, P. Poulain, J. Chapman, J. C. Fruchart, A. Tedgui, J. Najib-Fruchart, and B. Staels. 2000. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. [In Process Citation] Circulation. 101: 2411-2417.
33. Jiang, C., A. T. Ting, and B. Seed. 1998. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature. 391: 82-86.
34. Peper, R. J., W. Z. Tina, and M. M. Mickelson. 1968. Purification of lymphocytes and platelets by gradient centrifugation. J. Lab. Clin. Med. 72: 842-848.
35. Chou, Q., M. Russell, D. E. Birch, J. Raymond, and W. Bloch. 1992. Prevention of pre-PCR mis-priming and primer dimerization improves low-copy-number amplifications. Nucleic Acids Res. 20: 1717-1723.
36. Ramprasad, M. P., R. Li, W. A. Bradley, and S. H. Gianturco. 1995. Human THP-1 monocyte-macrophage membrane binding proteins: distinct receptor(s) for triglyceride-rich lipoproteins. Biochemistry. 34: 9126-9135.
37. Moore, K. J., E. D. Rosen, M. L. Fitzgerald, F. Randow, L. P. Andersson, D. Altshuler, D. S. Milstone, R. M. Mortensen, B. M. Spiegelman, and M. W. Freeman. 2001. The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat. Med. 7: 41-47.
38. Chawla, A., Y. Barak, L. Nagy, D. Liao, P. Tontonoz, and R. M. Evans. 2001. PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat. Med. 7: 48-52.
39. Chen, W., D. L. Silver, J. D. Smith, and A. R. Tall. 2000. Scavenger receptor-BI inhibits ATP-binding cassette transporter 1-mediated cholesterol efflux in macrophages. J. Biol. Chem. 275: 30794-30800.
40. Kodama, T., P. Reddy, C. Kishimoto, and M. Krieger. 1988. Purification and characterization of a bovine acetyl low density lipoprotein receptor. Proc. Natl. Acad. Sci. USA. 85: 9238-9242.
41. Endemann, G., L. W. Stanton, K. S. Madden, C. M. Bryant, R. T. White, and A. A. Protter. 1993. CD36 is a receptor for oxidized low density lipoprotein. J. Biol. Chem. 268: 11811-11816.
42. Boullier, A., D. A. Bird, M. K. Chang, E. A. Dennis, P. Friedman, K. Gillotre-Taylor, S. Horkko, W. Palinski, O. Quehenberger, P. Shaw, D. Steinberg, V. Terpstra, and J. L. Witztum. 2001. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann. N. Y. Acad. Sci. 947: 214-222.
43. Li, A. C., and C. K. Glass. 2002. The macrophage foam cell as a target for therapeutic intervention. Nat. Med. 8: 1235-1242.